
    
      BCD-017-2 is an open-label randomized phase II clinical study to compare the incidence of
      CTCAE grade 3/4 neutropenia after a single administration of recombinant human pegylated
      filgrastim empegfilgrastim (Extimia®) at a dose of 3 or 6 mg versus daily administration of
      filgrastim at a dose of 5 μg/kg/day for neutropenia prophylaxis in breast cancer patients
      receiving myelosuppressive chemotherapy.
    
  